H. Lundbeck A/S/€HLUNB
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About H. Lundbeck A/S
H. Lundbeck A/S is a Danish pharmaceutical company focused on the research, development, production, and marketing of pharmaceuticals for the treatment of brain disorders. Headquartered in Copenhagen, Denmark, Lundbeck's core business includes a portfolio of products addressing conditions such as depression, anxiety, schizophrenia, Alzheimer's disease, and Parkinson's disease. The company has a significant presence in the neuropharmaceuticals industry, striving to deliver innovative solutions to patients with unmet medical needs. Lundbeck operates internationally, distributing its products across multiple markets, supported by its strategic positioning in research and development. Unique competitive strengths include its dedicated focus on central nervous system disorders and ongoing investments in innovative therapies.
Ticker
€HLUNB
Sector
Primary listing
XGAT
Employees
5,700
Headquarters
Valby, Denmark
Website
H. Lundbeck A/S Metrics
BasicAdvanced
€5.6B
12.46
€0.47
0.30
€0.13
2.17%
Price and volume
Market cap
€5.6B
Beta
0.3
52-week high
€6.62
52-week low
€3.64
Average daily volume
165K
Dividend rate
€0.13
Financial strength
Current ratio
1.595
Quick ratio
1.078
Long term debt to equity
56.085
Total debt to equity
56.42
Dividend payout ratio (TTM)
27.06%
Interest coverage (TTM)
8.06%
Profitability
EBITDA (TTM)
952.054
Gross margin (TTM)
81.55%
Net profit margin (TTM)
14.82%
Operating margin (TTM)
22.85%
Effective tax rate (TTM)
15.56%
Revenue per employee (TTM)
€553,250
Management effectiveness
Return on assets (TTM)
7.39%
Return on equity (TTM)
14.70%
Valuation
Price to earnings (TTM)
12.457
Price to revenue (TTM)
1.846
Price to book
1.73
Price to tangible book (TTM)
-3.59
Price to free cash flow (TTM)
15.227
Free cash flow yield (TTM)
6.57%
Free cash flow per share (TTM)
0.385
Dividend yield (TTM)
2.17%
Forward dividend yield
2.17%
Growth
Revenue change (TTM)
13.79%
Earnings per share change (TTM)
34.80%
3-year revenue growth (CAGR)
11.62%
10-year revenue growth (CAGR)
5.61%
3-year earnings per share growth (CAGR)
41.53%
10-year earnings per share growth (CAGR)
-2.86%
3-year dividend per share growth (CAGR)
33.42%
Bulls say / Bears say
H. Lundbeck posted record annual revenue of DKK 22,004 million in 2024, up 14% at constant exchange rates, with growth coming from all regions
Strategic brands now account for 75% of total revenue, with Vyepti up 72% and Rexulti up 16% at CER in 2024, demonstrating success in brand-driven expansion
Positive results from the 12-month open-label extension of the Phase 1b/2a PACIFIC trial showed bexicaserin reduced median countable motor seizures by 59.3% in DEE patients, strengthening Lundbeck’s neuro-rare pipeline
Lundbeck’s adjusted EBITDA in FY 2024 dropped to DKK 5,146 million, impacted by DKK 420 million in integration expenses from the Longboard acquisition and a DKK 547 million impairment related to MAGLi projects, highlighting near-term margin pressure from these one-off costs
The FDA’s decision to convene a Psychopharmacologic Drugs Advisory Committee for Lundbeck’s brexpiprazole + sertraline PTSD sNDA, and an expected missed PDUFA action date, introduce regulatory uncertainties that could delay launch and revenue for the new indication
Lundbeck’s 2025 guidance forecasts revenue growth of only 7–10% and adjusted EBITDA growth of 5–11% at constant exchange rates—slower than 2024’s 14% revenue and 20% EBITDA growth rates—signaling moderated gains due to higher R&D spending
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for H. Lundbeck A/S stock?
H. Lundbeck A/S (HLUNB) has a market cap of €5.6B as of September 19, 2025.
What is the P/E ratio for H. Lundbeck A/S stock?
The price to earnings (P/E) ratio for H. Lundbeck A/S (HLUNB) stock is 12.46 as of September 19, 2025.
Does H. Lundbeck A/S stock pay dividends?
Yes, the H. Lundbeck A/S (HLUNB) stock pays dividends to shareholders. As of September 19, 2025, the dividend rate is €0.12727 and the yield is 2.17%. H. Lundbeck A/S has a payout ratio of 27.06% on a trailing twelve-month basis.
When is the next H. Lundbeck A/S dividend payment date?
The next H. Lundbeck A/S (HLUNB) dividend payment date is unconfirmed.
What is the beta indicator for H. Lundbeck A/S?
H. Lundbeck A/S (HLUNB) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.